Cyltezo Pen 40 Mg/0.4 Ml Starter Pack - shortage: What providers and prescribers need to know in 2026

Provider Briefing: Cyltezo Pen 40 Mg/0.4 Ml Starter Pack Availability in 2026

As a prescriber of biologic therapies, you've likely heard from patients struggling to fill their Cyltezo (adalimumab-dbll) prescriptions. While Cyltezo is not experiencing a traditional manufacturing shortage, the reality on the ground is that many patients face significant barriers to access.

This briefing covers the current supply landscape, prescribing considerations, and practical tools to help your patients maintain uninterrupted TNF-inhibitor therapy.

Timeline: How We Got Here

Understanding the current situation requires context on the adalimumab biosimilar market evolution:

• August 2017: Cyltezo (adalimumab-dbll) receives FDA approval as the first adalimumab biosimilar
• October 2021: Cyltezo becomes the first adalimumab biosimilar to receive interchangeable designation
• January 2023: Amjevita launches as the first adalimumab biosimilar to reach market
• July 2023: Cyltezo launches commercially
• 2023-2025: Multiple additional biosimilars enter the market (Hadlima, Hyrimoz, Yusimry, Simlandi, others)
• 2025-2026: PBM consolidation around preferred products leads to variable access across plans

Despite being first-to-approval and first-to-interchangeability, Cyltezo entered the market after Amjevita and has faced competitive headwinds in securing preferred formulary positions.

Prescribing Implications

Interchangeable Status

Cyltezo's interchangeable designation means pharmacists in most states can substitute it for Humira without prescriber intervention. Conversely, pharmacists may also substitute away from Cyltezo to a preferred product if allowed by state law and the prescription permits substitution.

If you specifically want your patient on Cyltezo, consider writing "dispense as written" (DAW) — though this may create insurance friction if Cyltezo is non-preferred on the patient's plan.

Clinical Equivalence

All FDA-approved adalimumab biosimilars have demonstrated biosimilarity to Humira through rigorous analytical, preclinical, and clinical studies. From a clinical standpoint, switching between adalimumab products does not result in meaningful differences in efficacy or immunogenicity based on available evidence.

The decision to prescribe Cyltezo specifically versus another adalimumab product should be driven by access, cost, and patient preference rather than clinical differentiation.

Dosing Consistency

The Cyltezo Pen Starter Pack uses the same 40 mg/0.4 mL concentration as Humira's citrate-free formulation. Dosing regimens remain the same across adalimumab products for all approved indications. No dose adjustment is required when switching between biosimilars.

Current Availability Picture

Cyltezo's availability challenges stem from several structural factors:

• Specialty pharmacy distribution: Like all adalimumab products, Cyltezo is distributed primarily through specialty channels. However, Cyltezo may have narrower specialty pharmacy network coverage compared to competitors with larger PBM contracts.
• PBM formulary positioning: Major PBMs (Express Scripts, CVS Caremark, Optum Rx) have each selected preferred adalimumab biosimilars based on rebate negotiations. Cyltezo may not be the preferred product on all major formularies.
• Retail pharmacy stocking: Retail pharmacies rarely stock Cyltezo. Even when a retail pharmacy can order it, turnaround times may be 3-7 business days.

We assign Cyltezo a findability score of 55 out of 100 — meaning it requires active effort to locate and fill, particularly through non-specialty channels.

Cost and Access Considerations

Pricing

Cyltezo is priced at approximately $5,800 to $6,500 per monthly supply at list price, representing a 5-15% discount versus Humira's list price of $6,900-$7,200. However, net pricing after rebates varies significantly by plan.

Patient Assistance

Boehringer Ingelheim offers two key programs:

• Cyltezo Copay Card: Eligible commercially insured patients may pay as little as $0 per month
• Boehringer Ingelheim Cares Foundation: Provides free medication to qualifying uninsured or underinsured patients

Prior Authorization

Many plans require prior authorization for Cyltezo, especially when it's not the preferred adalimumab product. Be prepared to submit clinical documentation supporting the use of Cyltezo specifically, including:

• Diagnosis and treatment history
• Reason for selecting Cyltezo over the preferred formulary alternative
• Prior treatment failures if applicable

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder for Providers offers real-time medication availability data that can help your office staff and patients locate Cyltezo (or alternatives) in stock at nearby pharmacies. This is particularly useful for patients who need to start therapy quickly.

Specialty Pharmacy Coordination

Consider establishing direct relationships with 2-3 specialty pharmacies that stock Cyltezo. This ensures a reliable channel when you prescribe it. Key specialty pharmacies to evaluate include:

• Accredo (Express Scripts network)
• CVS Specialty
• Optum Specialty Pharmacy
• BioPlus Specialty Pharmacy
• AllianceRx Walgreens Pharmacy

Electronic Prescribing

When e-prescribing, use the specific NDC for Cyltezo Pen 40 mg/0.4 mL Starter Pack to avoid confusion at the pharmacy level. Ensure the prescription is routed to a specialty pharmacy rather than a retail location.

Looking Ahead

The adalimumab biosimilar market is expected to continue evolving through 2026 and beyond. Key trends to watch:

• Further price competition: As more biosimilars compete, net pricing should continue to decrease
• PBM formulary shifts: Preferred products may change at plan renewal cycles, potentially improving or reducing Cyltezo access
• Interchangeability expansion: More biosimilars gaining interchangeable status may shift pharmacy substitution patterns
• High-concentration formulations: Some manufacturers are pursuing 80 mg/0.8 mL formulations for indications requiring higher loading doses

Final Thoughts

Cyltezo remains a clinically sound adalimumab option backed by interchangeable status and a citrate-free pen formulation. The access challenges your patients face are driven by market dynamics rather than supply problems.

As a prescriber, you can best support your patients by staying informed about formulary changes, maintaining specialty pharmacy relationships, and using tools like Medfinder for Providers to quickly identify available inventory.

For patient-facing resources, consider directing your patients to our articles on finding Cyltezo in stock and saving money on Cyltezo.